Cellectar Biosciences INC NEW

CLRBNASDAQ • USD
ThemeHealthcare - Oncology›Targeted Therapy & Precision Oncology
3.14 USD
↗ 0.00 (0.00%)AT CLOSE (11:59 AM EDT)
3.07
↘ 0.08 (2.39%)
POST MARKET (AS OF 07:48 PM EDT)
Post Market
AS OF 07:48 PM EDT
3.07
↘ 0.08 (2.39%)
🔴Market: CLOSED
Open?$2.98
High?$3.26
Low?$2.95
Prev. Close?$3.14
Volume?277.6K
Avg. Volume?2.1M
VWAP?$3.09
Rel. Volume?0.13x
Bid / Ask
Bid?$3.04 × 400
Ask?$3.15 × 3.4K
Spread?$0.11
Midpoint?$3.09
Valuation & Ratios
Market Cap?25.1M
Shares Out?8.0M
Float?7.6M
Float %?95.2%
P/E Ratio?N/A
P/B Ratio?7.52
EPS?-$2.61
Dividend?0.00%
Ex-Dividend?N/A

Shares of Cellectar Biosciences INC NEW (CLRB) are trading at $3.14. Technicals currently rate "Neutral" while our fundamental analysis reads "Sell". Key drivers include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. CLRB is fairly valued relative to its sector peers based on current multiples.

Technical & fundamental data as of May 29, 2026.

News
Profile
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. The products under development include Iopofosine, CLR 121125 ,CLR 121225 and others. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
Themes
Healthcare - Oncology›Targeted Therapy & Precision OncologyBiotech - Drug Development›Clinical-Stage Platforms
Employees
11
Market Cap
25.1M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.cellectar.com
Listed
2005-04-19
Address
100 CAMPUS DRIVE
FLORHAM PARK, NJ 07932
Phone: (608) 441-8120
Technical OutlookNeutral
Strong SellNeutralStrong Buy
Long-Term (Tide)?– Neutral(0/3)
Medium-Term (Wave)?– Neutral(0/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
77
Short Sent.?
43
Piotroski F-Score?0/9Weak
Altman Z-Score?-38.41Distress
Confidence?41%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?10.22%High
Short Interest?777.6K
Days to Cover?1.0
Free Float7.6M
Avg Daily Volume5.1M
Settlement Date2026-05-15
Financial Health
Current Ratio?1.90Adequate
Quick Ratio?1.90Adequate
Cash Ratio?1.71Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
83/100
P/E?
N/A▾
P/B?
Peers
100
S&P
25
7.52FAIR▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.8CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-624.9%WEAK▾
ROA?
S&P
3
-187.4%WEAK▾
Cash Flow & Enterprise
FCF?$-18589606
Enterprise Value?$16.7M
Fundamentals ratios updated end of day
MarketsMoversWatchlist